Acquired Hemophilia Medical Services in China

Acquired Hemophilia (AH) is a rare, life-threatening autoimmune bleeding disorder characterized by the spontaneous development of autoantibodies (inhibitors) against coagulation factor VIII (FVIII) in individuals with no prior personal or family history of hemophilia. Unlike congenital hemophilia, AH occurs de novo—typically in older adults—and results in impaired thrombin generation and defective fibrin clot formation. Pathogenesis centers on loss of immune tolerance: autoreactive B cells produce immunoglobulin G (IgG) antibodies that neutralize FVIII activity or accelerate its clearance, leading to markedly prolonged activated partial thromboplastin time (aPTT), undetectable or low FVIII activity (<1–5% of normal), and presence of an FVIII inhibitor confirmed by Bethesda or Nijmegen-Bethesda assay. Approximately 50% of cases are idiopathic; the remainder are associated with underlying conditions including autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus), malignancies (especially lymphoproliferative disorders and solid tumors in elderly patients), pregnancy (postpartum onset), and exposure to certain medications (e.g., interferon-alpha, penicillamine). Epidemiologically, AH has an incidence of 1–1.5 cases per million person-years, with median age at diagnosis of 70–80 years and no significant sex predilection—though slightly higher incidence is reported in women, possibly linked to postpartum cases. Risk factors include advanced age (>65 years), female sex (particularly in postpartum period), autoimmune comorbidity, active malignancy, and chronic inflammatory states. Clinically, patients present with sudden, severe, and often spontaneous bleeding—including extensive subcutaneous hematomas, muscle bleeds, gastrointestinal or urogenital hemorrhage, retroperitoneal bleeding, and, rarely, intracranial hemorrhage. Unlike congenital hemophilia, joint bleeds (hemarthroses) are uncommon. Delayed diagnosis is frequent due to nonspecific symptoms and lack of awareness, contributing to high early mortality (up to 20% within weeks), primarily from uncontrolled hemorrhage or complications of immunosuppressive therapy. Quality of life is profoundly impacted: patients experience acute pain, functional disability, anxiety about recurrent bleeding, treatment-related side effects (e.g., infections, hyperglycemia, hypertension from corticosteroids), hospitalization burden, and psychosocial distress. Long-term survivors may face chronic anemia, organ damage from recurrent bleeds, and persistent fatigue. Early recognition, rapid hemostatic control using bypassing agents (e.g., recombinant activated factor VII or activated prothrombin complex concentrate), and prompt initiation of immunosuppression (prednisone ± cyclophosphamide or rituximab) are critical to survival and functional recovery.

Acquired hemophilia A (AHA) is a rare, life-threatening autoimmune bleeding disorder characterized by the development of autoantibodies (inhibitors) against coagulation factor VIII (FVIII). Unlike congenital hemophilia, AHA occurs de novo in individuals with no prior personal or family history of bleeding disorders. The pathogenesis centers on loss of immune tolerance to endogenous FVIII, leading to IgG-mediated neutralization and/or accelerated clearance of the factor, resulting in impaired thrombin generation and defective fibrin clot formation.

Common causes of AHA include underlying autoimmune conditions, malignancies, and pregnancy. Approximately 50% of cases are idiopathic (no identifiable etiology), while ~30–40% are associated with autoimmune diseases—most frequently rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren syndrome, and inflammatory bowel disease. Malignancy accounts for 10–20% of cases, particularly hematologic neoplasms (e.g., lymphoma, chronic lymphocytic leukemia) and solid tumors (e.g., prostate, gastric, lung cancers); the inhibitor may arise from aberrant B-cell activation or tumor-associated immune dysregulation. Postpartum AHA represents a distinct clinical subset, typically occurring within 6 months after delivery, with peak incidence around 2–4 weeks postpartum; its pathophysiology likely involves hormonal shifts, placental antigen exposure, and postpartum immune reconstitution.

Triggers of AHA are often multifactorial and may include immunologic stressors such as infections (e.g., hepatitis C, HIV, CMV), recent vaccinations (rarely reported), surgical procedures, or drug exposures. Certain medications—including antibiotics (e.g., sulfonamides), antiepileptics (e.g., phenytoin), anti-TNF agents, and immune checkpoint inhibitors—have been temporally associated with inhibitor development, though causality remains unproven in most instances. In elderly patients, age-related immunosenescence and clonal B-cell expansion may lower the threshold for autoantibody formation.

Established risk factors include advanced age (median onset 65–75 years), female sex (particularly in postpartum cases), and comorbid autoimmune or lymphoproliferative disorders. Age is the strongest demographic risk factor: over 80% of cases occur in individuals aged ≥65 years, reflecting cumulative immune dysregulation, thymic involution, and increased prevalence of monoclonal gammopathies. Female predominance is observed overall (≈60–70% of cases), driven largely by the postpartum cohort; however, in older adults, the sex distribution becomes more balanced or slightly male-predominant outside pregnancy-related cases.

Genetic factors do not confer Mendelian inheritance in AHA, but polymorphisms in immune-regulatory genes influence susceptibility. HLA class II alleles—particularly *DRB1*03:01, *DRB1*15:01, and *DQB1*02:01—are overrepresented in AHA patients and are implicated in aberrant FVIII peptide presentation to CD4+ T cells. Variants in genes encoding cytokines (e.g., *TNFA*, *IL10*), Fcγ receptors (*FCGR2A*, *FCGR3A*), and CTLA-4 (*CTLA4*) modulate B-cell activation thresholds and regulatory T-cell function. Importantly, germline mutations in *F8* are absent; however, somatic mutations in B-cell receptor genes or epigenetic dysregulation in plasma cell clones may contribute to pathogenic antibody production in malignancy-associated cases.

Environmental factors play a contributory role through modulation of immune homeostasis. Chronic antigenic stimulation—such as persistent viral infection (e.g., HBV, HCV), microbiome dysbiosis, or environmental toxins—may promote bystander activation or molecular mimicry. Smoking has been weakly associated with increased risk in some cohort studies, potentially via oxidative stress-induced endothelial damage and neoantigen exposure. Geographic and socioeconomic variables show no consistent epidemiologic pattern, though diagnostic delay is more common in resource-limited settings due to low clinical suspicion and limited access to inhibitor assays (Bethesda assay, Nijmegen-Bethesda assay) and FVIII activity testing. Notably, unlike congenital hemophilia, AHA is not linked to consanguinity, X-chromosome inheritance, or prenatal exposures.

In summary, AHA arises from complex interactions among aging-related immune dysfunction, genetic predisposition to loss of self-tolerance, underlying systemic disease, and environmental immunomodulators. Early recognition hinges on maintaining high clinical suspicion in patients presenting with new-onset mucocutaneous or deep soft-tissue bleeding, prolonged APTT uncorrected by mixing studies, and normal PT and platelet count—especially in older adults or those with autoimmune comorbidities.

Acquired hemophilia (AH) is a rare, life-threatening autoimmune bleeding disorder characterized by the development of autoantibodies (inhibitors) against coagulation factor VIII (FVIII), leading to impaired intrinsic pathway function and uncontrolled hemorrhage. Unlike congenital hemophilia, AH occurs de novo in individuals with no prior personal or family history of bleeding diathesis, typically affecting older adults (median age 60–80 years), though cases have been reported across all age groups, including postpartum women. Early symptoms are often subtle and nonspecific, contributing to frequent diagnostic delays. Patients may initially present with mild, recurrent mucocutaneous bleeding—such as easy bruising (ecchymoses) disproportionate to trauma, prolonged epistaxis, gingival oozing after dental procedures, or menorrhagia in premenopausal women. Petechiae are uncommon, distinguishing AH from thrombocytopenic disorders. A hallmark early sign is spontaneous soft-tissue hematoma formation—often deep, painful, and expanding—without antecedent injury; these may localize to the extremities, trunk, or retroperitoneum and are frequently misattributed to musculoskeletal strain or trauma. In postpartum patients, delayed-onset postpartum hemorrhage (typically 2–6 weeks after delivery) with persistent vaginal bleeding, uterine atony unresponsive to standard therapy, or massive pelvic hematoma may be the initial manifestation.

Typical symptoms reflect severe FVIII deficiency (functional activity often <1–5% of normal). The most characteristic presentation is sudden, spontaneous, and often massive soft-tissue or muscle bleeding—particularly in the limbs, neck, or abdominal wall—with rapid expansion, tense swelling, and severe pain. Hemarthroses are notably rare (<5% of cases), contrasting sharply with congenital hemophilia A and serving as a key clinical differentiator. Other classic manifestations include gastrointestinal bleeding (hematemesis, melena, or hematochezia), hematuria (often macroscopic and painless), and intracranial hemorrhage (ICH)—a catastrophic complication occurring in ~3–5% of cases and carrying >30% mortality. Bleeding into fascial planes (e.g., iliopsoas, gluteal, or thigh compartments) may cause compartment syndrome, nerve compression (e.g., femoral neuropathy), or limb ischemia. Post-surgical or post-procedural hemorrhage is disproportionately severe: patients undergoing minor interventions (e.g., tooth extraction, endoscopy, or biopsy) may experience torrential, refractory bleeding requiring emergent transfusion and intensive care.

Accompanying symptoms frequently reflect systemic inflammation or underlying etiology. Approximately 50% of AH cases are idiopathic; the remainder are associated with autoimmune conditions (e.g., rheumatoid arthritis, SLE, inflammatory bowel disease), malignancies (especially lymphoproliferative disorders, solid tumors, and prostate cancer), pregnancy/postpartum state, dermatologic diseases (e.g., psoriasis, alopecia areata), or drug exposure (e.g., penicillamine, interferon-alpha, immune checkpoint inhibitors). Patients may therefore exhibit constitutional symptoms such as fatigue, low-grade fever, weight loss, arthralgias, or skin rashes. Laboratory evidence of immune dysregulation—including elevated ESR, CRP, RF, or ANA—may be present but is neither sensitive nor specific. Notably, platelet count, PT, fibrinogen, and D-dimer are typically normal, helping distinguish AH from DIC or primary fibrinolysis.

Complications arise both from hemorrhage and its management. Life-threatening hemorrhages include airway compromise from neck or oral cavity hematoma, hypovolemic shock, renal failure secondary to obstructive ureteral hematoma or acute tubular necrosis, and spinal cord compression from epidural hematoma. ICH remains the leading cause of early mortality. Therapeutic complications include anaphylaxis or thrombotic events with bypassing agents (e.g., activated prothrombin complex concentrate [aPCC] or recombinant activated factor VII [rFVIIa]), especially in elderly or comorbid patients. Immunosuppressive therapy (e.g., corticosteroids ± cyclophosphamide or rituximab) carries risks of infection (including Pneumocystis jirovecii pneumonia), hyperglycemia, osteonecrosis, cytopenias, and secondary malignancy. Delayed diagnosis (>2 weeks from symptom onset) correlates strongly with increased mortality and morbidity.

Diagnosis hinges on high clinical suspicion and targeted coagulation testing. Initial screening reveals isolated prolongation of the activated partial thromboplastin time (aPTT) with normal PT, INR, platelet count, fibrinogen, and thrombin time. Mixing studies (1:1 mix of patient plasma with normal pooled plasma incubated 1–2 hours at 37°C) demonstrate failure of aPTT correction—confirming presence of an inhibitor. Subsequent quantification of FVIII activity (by one-stage clotting assay) shows marked reduction (<15%); parallel measurement of FVIII inhibitor titer via Bethesda or Nijmegen-Bethesda assay (NBA) confirms diagnosis (titer ≥0.6 BU/mL is diagnostic). Additional testing includes FVIII antigen level (usually preserved, distinguishing AH from FVIII gene mutations), von Willebrand factor antigen and activity (normal, excluding von Willebrand disease), and exclusion of lupus anticoagulant (which may cause aPTT prolongation but does not inhibit FVIII and typically shows normal FVIII activity). Comprehensive evaluation mandates age-appropriate malignancy screening (CT chest/abdomen/pelvis, mammography, colonoscopy, PSA, LDH, peripheral blood flow cytometry), autoimmune serology (ANA, ENA, RF, anti-dsDNA), and obstetric assessment in women of childbearing age.

Differential diagnosis is critical to avoid mismanagement. Congenital hemophilia A must be excluded via detailed personal/family history and genetic testing if indicated; hemarthroses and childhood onset favor congenital disease. Lupus anticoagulant presents with aPTT prolongation but normal FVIII activity and absence of bleeding (often associated with thrombosis). Acquired von Willebrand syndrome (AVWS) may mimic AH but features low VWF:Ag, VWF:RCo, and FVIII (due to VWF-dependent stabilization), often in context of lymphoproliferative disorders or cardiovascular disease. DIC shows global coagulopathy (low platelets, low fibrinogen, elevated D-dimer, prolonged PT/aPTT) and organ dysfunction. Heparin-induced thrombocytopenia (HIT) may cause aPTT prolongation but is associated with thrombosis, not bleeding, and positive anti-PF4 antibodies. Factor II, V, or X deficiencies are exceedingly rare and present with combined PT/aPTT prolongation. Finally, amyloidosis-related factor X deficiency may cause isolated aPTT elevation but is distinguished by organomegaly, proteinuria, and tissue biopsy confirmation. Accurate differentiation guides urgent hemostatic intervention and appropriate immunosuppression, directly impacting survival.

Acquired hemophilia A (AHA) is a rare, life-threatening autoimmune bleeding disorder characterized by the development of autoantibodies (inhibitors) against coagulation factor VIII (FVIII). Unlike congenital hemophilia, AHA occurs de novo in individuals with no prior personal or family history of bleeding diathesis—typically in older adults (median age 60–80 years), though it may affect any age group, including postpartum women. The condition carries significant morbidity and mortality, primarily due to uncontrolled spontaneous or trauma-induced hemorrhage (e.g., muscle hematomas, gastrointestinal, retroperitoneal, or intracranial bleeding), with reported mortality rates of 15–25% within the first year. Management requires a multidisciplinary approach coordinated by hematologists, immunologists, transfusion medicine specialists, and critical care teams.

Conservative treatment forms the cornerstone of initial management and focuses on two parallel objectives: (1) immediate hemostatic control and (2) eradication of the pathogenic autoantibody. Hemostatic support must be initiated promptly upon suspicion—even before confirmatory laboratory testing—to prevent irreversible organ damage or exsanguination. Patients should be admitted to a specialized hematology unit with 24/7 access to coagulation laboratories, point-of-care viscoelastic testing (e.g., thromboelastography), and on-site blood bank services. Bed rest, strict avoidance of intramuscular injections, invasive procedures (unless lifesaving and meticulously planned), and antiplatelet/anticoagulant agents is mandatory. Serial clinical assessment—including neurological, abdominal, and musculoskeletal examinations—is essential to detect occult bleeding. Monitoring includes serial FVIII activity assays, inhibitor titer (Bethesda assay), global coagulation tests (aPTT, fibrinogen, D-dimer), and complete blood count. In asymptomatic patients with low-titer inhibitors (<5 BU/mL) and no active bleeding, observation alone may be considered—but only after thorough risk stratification and shared decision-making.

Pharmacologic therapy is stratified into hemostatic agents and immunosuppressive regimens. For acute bleeding, bypassing agents are first-line: recombinant activated factor VII (rFVIIa; 90 µg/kg IV bolus every 2–3 hours until hemostasis) or activated prothrombin complex concentrate (aPCC; FEIBA®, 50–100 IU/kg IV, repeated as needed, with cumulative daily dose capped at 200 IU/kg to mitigate thrombotic risk). rFVIIa is preferred in patients with high inhibitor titers (>10 BU/mL), renal impairment, or thrombotic history; aPCC may be favored when cost or availability is limiting—but requires careful monitoring for disseminated intravascular coagulation or arterial thrombosis. Human plasma-derived FVIII is ineffective and contraindicated due to neutralization by inhibitors. Desmopressin has no role in AHA. Immunosuppression aims to eliminate inhibitor-producing plasma cells. First-line therapy is corticosteroids (prednisone 1 mg/kg/day orally, tapered over 4–6 weeks) combined with cyclophosphamide (1.5–2 mg/kg/day orally for 4–6 weeks). This regimen achieves complete remission (CR; inhibitor undetectable + FVIII >50 IU/dL) in ~70–80% of patients within 4–8 weeks. For steroid-intolerant or refractory cases, rituximab (375 mg/m² IV weekly × 4 doses) is recommended—particularly in elderly patients or those with comorbidities precluding alkylating agents. Emerging options include calcineurin inhibitors (tacrolimus), proteasome inhibitors (bortezomib), and newer B-cell modulators (e.g., obinutuzumab), though evidence remains limited to case series and small trials. All immunosuppressed patients require Pneumocystis jirovecii prophylaxis (e.g., trimethoprim-sulfamethoxazole), vaccination updates (non-live vaccines only), and vigilant infection surveillance.

Surgical intervention is rarely indicated and reserved exclusively for life- or limb-threatening hemorrhage unresponsive to medical hemostasis—such as expanding retroperitoneal hematoma causing compartment syndrome or airway compromise from neck hematoma. Surgery must be performed in centers with integrated hematology-thrombosis support, using intraoperative rFVIIa or aPCC infusions guided by real-time coagulation monitoring. Elective surgery is contraindicated during active disease; if unavoidable (e.g., urgent cancer resection), it must be preceded by ≥2 weeks of effective immunosuppression and confirmed inhibitor titer reduction (>50% decline and <5 BU/mL). Preoperative FVIII recovery testing is not predictive and should not delay therapy.

Treatment advantages in China include rapid diagnostic capacity through nationally accredited hemophilia reference laboratories (e.g., at Peking Union Medical College Hospital and Ruijin Hospital), standardized inhibitor assays aligned with ISTH guidelines, and centralized pharmacovigilance for bypassing agents. China’s National Reimbursement Drug List (NRDL) now covers rFVIIa and rituximab for AHA, significantly improving accessibility. Multicenter registries (e.g., the Chinese Acquired Hemophilia Registry, CAHR) facilitate real-world outcome tracking and protocol refinement. Additionally, China’s robust telehematology infrastructure enables timely remote consultation for rural referrals, reducing time-to-treatment. Traditional Chinese Medicine (TCM) adjuncts are sometimes used under hematologist supervision for supportive symptom management (e.g., astragalus for immune modulation), but TCM is never substituted for evidence-based immunosuppression or hemostatic therapy.

Recovery advice emphasizes long-term vigilance. Patients achieving CR require monthly FVIII activity and inhibitor titer monitoring for at least 6 months, then quarterly for 1 year, given the 10–15% relapse risk—most commonly within 6 months of immunosuppression cessation. Education on early bleeding recognition (e.g., prolonged oozing, new bruising, hematuria) and emergency action plans—including carrying an AHA identification card with treatment protocol—is critical. Physical rehabilitation should be gradual and supervised by physiotherapists experienced in coagulopathies; aquatic therapy may be introduced once FVIII >50 IU/dL and inhibitor-negative. Psychosocial support is integral: depression and anxiety prevalence exceeds 40% in AHA survivors, warranting routine screening and referral to mental health services. Vaccination against hepatitis A/B, influenza, and pneumococcus is strongly encouraged. Pregnancy counseling is essential for women of childbearing potential, as postpartum AHA recurrence risk is elevated. Finally, patients should avoid NSAIDs indefinitely and consult hematologists before any new medication, including herbal supplements, due to unpredictable interactions with immunosuppressants or coagulation pathways.